Fig. 2
From: The emerging possibility of the use of geniposide in the treatment of cerebral diseases: a review
The therapeutic effect of geniposide on cerebral ischaemic disease. Geniposide enhances GluN2A-dependent survival signals, including pAKT, pERK and PSD-95, and works by reducing the expression of iNOS and NF-κB and inhibiting the release of the inflammatory factors tumour necrosis factor-α (TNF-α) and IL-6. In addition, geniposide activates the PI3K/AKT and Wnt/catenin pathways by upregulating the expression of H19 in PC-12 cells